VYNE
VYNE Therapeutics Inc
Halal Rating :
Last Price
$2.71
Last updated:
Market Cap
-
7D Change
-10.17%
1 Year Change
42.04%
Company Overview
Industries
Exchange
Next Earnings Date
VYNE Therapeutics Inc. is a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is developing VYN201, a locally-administered pan-BET inhibitor, and VYN202, a selective BET inhibitor for oral administration, for the treatment of vitiligo and other immuno-inflammatory conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $121000.0 | $13.21m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $198000.0 | $10.59m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $98000.0 | $7.48m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate VYNE Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.